LEADER 03728nam 2200505z- 450 001 9910557407103321 005 20211118 035 $a(CKB)5400000000043605 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/73718 035 $a(oapen)doab73718 035 $a(EXLCZ)995400000000043605 100 $a20202111d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMultiple Sclerosis - From Bench to Bedside: Currents Insights into Pathophysiological Concepts and Their Potential Impact on Patients 210 $cFrontiers Media SA$d2020 215 $a1 online resource (253 p.) 311 08$a2-88963-566-X 330 $aResearch and advances in the treatment of Multiple Sclerosis (MS) is a story of growing success. Great progress has been made in identifying the molecular mechanisms that can be utilized to develop highly efficacious treatments for MS patients. Since the middle of the last century, when studies using an inflammatory autoimmune model of MS i.e. experimental autoimmune encephalitis (EAE) were initiated, research on MS has since led to an enormous growth of knowledge. The limitations arising from these animal models have been partially compensated by insights generated from histopathological, immunological, genetic, imaging and clinical studies of MS. The importance of T cells and, recently of B cells, in MS has been elucidated and the significance of CNS resident cells, particularly in the progressive course of MS has been highlighted. The importance of environmental factors and genetic predisposition have also been recognized and the interaction between th e individual and its environment seems to play key roles in the pathogenesis of this disease. However, definite causative agent(s) or single gene(s) involved in MS still remain unidentified. A deeper understanding of the immunological pathways involved goes hand in hand with further improving therapy for MS. Focal inflammation in MS, caused by de novo CNS infiltration, can be prevented effectively using peripherally-acting drugs. However, diffuse CNS intrinsic inflammation and neurodegeneration are not targeted by the current arsenal of therapeutics and patients with progressive disease courses remain difficult to treat. Generating insights into pathophysiological processes and the clinical translation of this knowledge have been a formula of success for treating inflammatory diseases. The future will show whether this will hold true for CNS-trapped inflammation and neurodegeneration and whether the ultimate goal - truly curing MS - will be possible. 517 $aMultiple Sclerosis – From Bench to Bedside 517 $aMultiple Sclerosis ? From Bench to Bedside 606 $aImmunology$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $aMultiple Sclerois and Neuroimmunology 610 $aMultiple Sclerosis 610 $aMultiple sclerosis - drug therapy 610 $aMultiple sclerosis - epidemiology 610 $aMultiple sclerosis - etiology 615 7$aImmunology 615 7$aMedicine and Nursing 700 $aStefan Rommer$b Paulus$4edt$01286910 702 $aWeber$b Martin S$4edt 702 $aIlles$b Zsolt$4edt 702 $aZettl$b Uwe K$4edt 702 $aStefan Rommer$b Paulus$4oth 702 $aWeber$b Martin S$4oth 702 $aIlles$b Zsolt$4oth 702 $aZettl$b Uwe K$4oth 906 $aBOOK 912 $a9910557407103321 996 $aMultiple Sclerosis ? From Bench to Bedside: Currents Insights into Pathophysiological Concepts and Their Potential Impact on Patients$93019986 997 $aUNINA